Alpha Teknova Reports Q4 Loss with Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Source: NASDAQ.COM
- Financial Overview: Alpha Teknova reported a fourth-quarter loss of $4.76 million, translating to a loss of $0.09 per share, which is an improvement from last year's loss of $5.72 million or $0.11 per share, indicating gradual financial recovery.
- Revenue Growth: The company achieved fourth-quarter revenue of $9.98 million, a 7.7% increase from $9.27 million last year, reflecting enhanced sales capabilities amid recovering market demand, potentially laying the groundwork for future profitability.
- Year-over-Year Comparison: Although still in a loss position, Alpha Teknova's reduced loss compared to last year suggests progress in cost control and operational efficiency, which may attract investor interest.
- Market Outlook: With revenue growth and reduced losses, Alpha Teknova is positioned for improved financial performance in upcoming quarters, enhancing its competitiveness and market confidence in the biotechnology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TKNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TKNO
Wall Street analysts forecast TKNO stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.950
Low
7.00
Averages
7.00
High
7.00
Current: 4.950
Low
7.00
Averages
7.00
High
7.00
About TKNO
Alpha Teknova, Inc. is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The Company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It offers a range of standard and specialty pre-poured media plates for a variety of applications including bacteria, fungi, and nematode growth. Its two primary product categories include Lab Essentials and Clinical Solutions. Its core Lab Essentials products consist of commonly used catalog solutions and customer-specified formulations. Its Clinical Solutions products are custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Alpha Teknova Reports Q4 Loss with Revenue Growth
- Financial Overview: Alpha Teknova reported a fourth-quarter loss of $4.76 million, translating to a loss of $0.09 per share, which is an improvement from last year's loss of $5.72 million or $0.11 per share, indicating gradual financial recovery.
- Revenue Growth: The company achieved fourth-quarter revenue of $9.98 million, a 7.7% increase from $9.27 million last year, reflecting enhanced sales capabilities amid recovering market demand, potentially laying the groundwork for future profitability.
- Year-over-Year Comparison: Although still in a loss position, Alpha Teknova's reduced loss compared to last year suggests progress in cost control and operational efficiency, which may attract investor interest.
- Market Outlook: With revenue growth and reduced losses, Alpha Teknova is positioned for improved financial performance in upcoming quarters, enhancing its competitiveness and market confidence in the biotechnology sector.
See More
Alpha Teknova Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: In Q4 2025, Alpha Teknova reported total revenue of $10 million, a 7% increase from $9.3 million in Q4 2024, indicating sustained competitiveness in the market and potential for future business expansion.
- Expanded Customer Base: The number of active customers purchasing clinical products rose to 60, a 25% increase from 2024, which not only enhances market share but also lays a solid foundation for future revenue growth.
- Improved Gross Margin: The gross margin for Q4 2025 was 32.5%, up from 23.0% in Q4 2024, reflecting successful cost control and pricing strategies, which are expected to further enhance profitability.
- Optimistic Future Outlook: Management projects total revenue guidance for 2026 to be between $42 million and $44 million, implying approximately 6% growth at the midpoint, demonstrating confidence in future market opportunities, particularly in the commercialization of new therapies.
See More
Alpha Teknova Q4 Earnings Exceed Expectations
- Earnings Beat: Alpha Teknova reported a Q4 GAAP EPS of $0.09, surpassing expectations by $0.18, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $10 million, reflecting a 7.5% year-over-year increase and exceeding expectations by $0.39 million, demonstrating its sustained competitiveness in the market, which may attract more investor interest.
- Positive Market Reaction: Given the strong earnings report, Alpha Teknova's stock price is likely to experience a positive impact, further enhancing the company's market position in the biotechnology sector and drawing attention from institutional investors.
- Optimistic Outlook: With ongoing operational optimizations and product line enhancements, the company is expected to maintain growth momentum in the coming quarters, solidifying its leadership position in the industry.
See More
Alpha Teknova (TKNO) Third Quarter 2025 Earnings Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
See More
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Alpha Teknova Reports Q4 Loss with Revenue Growth
- Financial Overview: Alpha Teknova reported a fourth-quarter loss of $4.76 million, translating to a loss of $0.09 per share, which is an improvement from last year's loss of $5.72 million or $0.11 per share, indicating gradual financial recovery.
- Revenue Growth: The company achieved fourth-quarter revenue of $9.98 million, a 7.7% increase from $9.27 million last year, reflecting enhanced sales capabilities amid recovering market demand, potentially laying the groundwork for future profitability.
- Year-over-Year Comparison: Although still in a loss position, Alpha Teknova's reduced loss compared to last year suggests progress in cost control and operational efficiency, which may attract investor interest.
- Market Outlook: With revenue growth and reduced losses, Alpha Teknova is positioned for improved financial performance in upcoming quarters, enhancing its competitiveness and market confidence in the biotechnology sector.
See More
Alpha Teknova Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: In Q4 2025, Alpha Teknova reported total revenue of $10 million, a 7% increase from $9.3 million in Q4 2024, indicating sustained competitiveness in the market and potential for future business expansion.
- Expanded Customer Base: The number of active customers purchasing clinical products rose to 60, a 25% increase from 2024, which not only enhances market share but also lays a solid foundation for future revenue growth.
- Improved Gross Margin: The gross margin for Q4 2025 was 32.5%, up from 23.0% in Q4 2024, reflecting successful cost control and pricing strategies, which are expected to further enhance profitability.
- Optimistic Future Outlook: Management projects total revenue guidance for 2026 to be between $42 million and $44 million, implying approximately 6% growth at the midpoint, demonstrating confidence in future market opportunities, particularly in the commercialization of new therapies.
See More
Alpha Teknova Q4 Earnings Exceed Expectations
- Earnings Beat: Alpha Teknova reported a Q4 GAAP EPS of $0.09, surpassing expectations by $0.18, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $10 million, reflecting a 7.5% year-over-year increase and exceeding expectations by $0.39 million, demonstrating its sustained competitiveness in the market, which may attract more investor interest.
- Positive Market Reaction: Given the strong earnings report, Alpha Teknova's stock price is likely to experience a positive impact, further enhancing the company's market position in the biotechnology sector and drawing attention from institutional investors.
- Optimistic Outlook: With ongoing operational optimizations and product line enhancements, the company is expected to maintain growth momentum in the coming quarters, solidifying its leadership position in the industry.
See More
Alpha Teknova (TKNO) Third Quarter 2025 Earnings Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
See More
